Literature DB >> 20160064

Critical role of G(alpha)12 and G(alpha)13 for human small cell lung cancer cell proliferation in vitro and tumor growth in vivo.

Marius Grzelinski1, Olaf Pinkenburg, Thomas Büch, Maike Gold, Stefanie Stohr, Hermann Kalwa, Thomas Gudermann, Achim Aigner.   

Abstract

PURPOSE: In small cell lung cancer cells (SCLC), various autocrine stimuli lead to the parallel activation of G(q/11) and G(12/13) proteins. Although the contribution of the G(q/11)-phospholipase C-beta cascade to mitogenic effects in SCLC cells is well established, the relevance of G(12/13) signaling is still elusive. In other tumor entities, G(12/13) activation promotes invasiveness without affecting cellular proliferation. Here, we investigate the role of G(12/13)-dependent signaling in SCLC. EXPERIMENTAL
DESIGN: We used small hairpin RNA-mediated targeting of G(alpha)(12), G(alpha)(13), or both in H69 and H209 cells and analyzed the effects of G(alpha)(12) and/or G(alpha)(13) knockdown on tumor cells in vitro, tumor growth in vivo, and mitogen-activated protein kinase (MAPK) activation.
RESULTS: Lentiviral expression of small hairpin RNAs resulted in robust and specific G(alpha)(12) and G(alpha)(13) knockdown as well as markedly inhibited proliferation, colony formation, and bradykinin-promoted stimulation of cell growth. Analyzing the activation status of all three major MAPK families revealed nonredundant functions of G(alpha)(12) and G(alpha)(13) in SCLC and a marked p42/p44 activation upon G(alpha)(12)/G(alpha)(13) knockdown. In a s.c. tumor xenograft mouse model, G(alpha)(12) or G(alpha)(13) downregulation led to decreased tumor growth due to reduced tumor cell proliferation. More importantly, G(alpha)(12)/G(alpha)(13) double knockdown completely abolished H69 tumorigenicity in mice.
CONCLUSIONS: G(alpha)(12) and G(alpha)13) exert a complex pattern of nonredundant effects in SCLC, and in contrast to other tumor types, SCLC cell proliferation in vitro and tumorigenicity in vivo critically depend on G(12/13) signaling. Due to the complete abolishment of tumorgenicity in our study, RNAi-mediated double knockdown may provide a promising new avenue in SCLC treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160064     DOI: 10.1158/1078-0432.CCR-09-1873

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Y M Yang; W H Lee; C G Lee; J An; E-S Kim; S H Kim; S-K Lee; C H Lee; D N Dhanasekaran; A Moon; S Hwang; S J Lee; J-W Park; K M Kim; S G Kim
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

Review 2.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

Review 3.  Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.

Authors:  Jinho Park; Joonyoung Park; Yihua Pei; Jun Xu; Yoon Yeo
Journal:  Adv Drug Deliv Rev       Date:  2015-12-10       Impact factor: 15.470

4.  Mitogenic Signaling by the gep Oncogene Involves the Upregulation of S-Phase Kinase-Associated Protein 2.

Authors:  Rangasudhagar Radhakrishnan; Ji Hee Ha; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2010-10

5.  Thwarting of Lphn3 Functions in Cell Motility and Signaling by Cancer-Related GAIN Domain Somatic Mutations.

Authors:  Monserrat Avila-Zozaya; Brenda Rodríguez-Hernández; Feliciano Monterrubio-Ledezma; Bulmaro Cisneros; Antony A Boucard
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

6.  Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer.

Authors:  Hiroshi Yagi; Ichiro Onoyama; Kazuo Asanoma; Minoru Kawakami; Shoji Maenohara; Keisuke Kodama; Yumiko Matsumura; Norio Hamada; Emiko Hori; Kazuhisa Hachisuga; Masafumi Yasunaga; Tatsuhiro Ohgami; Kaoru Okugawa; Hideaki Yahata; Kiyoko Kato
Journal:  Cancer Gene Ther       Date:  2022-10-18       Impact factor: 5.854

Review 7.  Signaling mechanisms and physiological functions of G-protein Gα13 in blood vessel formation, bone homeostasis, and cancer.

Authors:  Viktoriya Syrovatkina; Xin-Yun Huang
Journal:  Protein Sci       Date:  2018-11-15       Impact factor: 6.725

8.  Gα12 ablation exacerbates liver steatosis and obesity by suppressing USP22/SIRT1-regulated mitochondrial respiration.

Authors:  Tae Hyun Kim; Yoon Mee Yang; Chang Yeob Han; Ja Hyun Koo; Hyunhee Oh; Su Sung Kim; Byoung Hoon You; Young Hee Choi; Tae-Sik Park; Chang Ho Lee; Hitoshi Kurose; Mazen Noureddin; Ekihiro Seki; Yu-Jui Yvonne Wan; Cheol Soo Choi; Sang Geon Kim
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

9.  Heterotrimeric G-protein alpha-12 (Gα12) subunit promotes oral cancer metastasis.

Authors:  Chai Phei Gan; Vyomesh Patel; Constantinos M Mikelis; Rosnah Binti Zain; Alfredo A Molinolo; Mannil Thomas Abraham; Soo-Hwang Teo; Zainal Ariff Abdul Rahman; J Silvio Gutkind; Sok Ching Cheong
Journal:  Oncotarget       Date:  2014-10-30

10.  Determinant role for the gep oncogenes, Gα12/13, in ovarian cancer cell proliferation and xenograft tumor growth.

Authors:  Ji Hee Ha; Rohini Gomathinayagam; Mingda Yan; Muralidharan Jayaraman; Rajagopal Ramesh; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2015-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.